Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2016. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMR), or Connected Persons, specifically regarding the sale or withholding of shares to meet tax liabilities following the vesting of awards under the 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific equity transactions and does not contain consolidated financial statements.
Material Changes and Transaction Details
The filing details two specific transactions executed on February 12, 2016, to satisfy tax obligations:
- Ordinary Shares: Mrs. K Thomson (Connected Person of PDMR Mr. P Thomson) sold 633 Ordinary Shares at a fair market value of £14.06 per share.
- American Depositary Shares (ADS): Dr. K Slaoui (Connected Person of Director Dr. M Slaoui) had 386 ADSs withheld at a fair market value of $39.15 per ADS.
Both transactions relate to awards granted in 2012. The Company was advised of these transactions on February 16, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the routine disclosure of director-related share transactions.
Important Facts for Investor Verification
- Verify the total shareholding positions of Mr. P Thomson and Dr. M Slaoui following these tax-related disposals.
- Confirm the fair market value prices (£14.06 and $39.15) align with the trading prices on February 12, 2016.
- Note that this filing is a regulatory disclosure of insider transactions and does not reflect the company's operational performance for the period.